...
首页> 外文期刊>Clinical Science >miR-296/scribble axis is deregulated in human breast cancer and miR-296 restoration reduces tumour growth in vivo
【24h】

miR-296/scribble axis is deregulated in human breast cancer and miR-296 restoration reduces tumour growth in vivo

机译:MiR-296 /涂鸦轴在人乳腺癌中解毒,MiR-296恢复可降低体内肿瘤生长

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

miR-296-5p is a central regulator of signalling pathways affecting development, stem cell differentiation and cancer. We hypothesized that miR-296-5p is involved in breast cancer onset and progression possibly through regulation of its target SCRIB (Scribble), a polarity protein recently implicated in the acquisition of cancer stem cell traits and in cell motility. We found that miR-296-5p levels were consistently reduced in human breast cancer tissues compared with non-neoplastic mammary parenchyma, and low expression of this miRNA predicted shorter disease-free survival independently of classic clinicopathological parameters. Further, reduced miR-296-5p levels were significantly correlated with an earlier spread of cancer in the overall series and with distant metastases in the subset. In contrast with its regulator, SCRIB was overexpressed and mislocalized in primary breast cancers or locoregional or distant metastatic lesions compared with normal parenchyma. Notably, SCRIB mislocalization was associated with overall survival, metastatic spread and organ tropism in patients with breast cancer. Finally, direct injection of a precursor miR-296-5p into tumours of a breast cancer xenograft model significantly decreased tumour growth. Our results show that the miR-296-5p/SCRIB axis plays a role in breast carcinogenesis and an miR-296-5p-based therapeutic approach hampers breast cancer tumour growth in vivo. Modulation of miR-296-5p may represent a new therapeutic option for patients with breast cancer.
机译:MiR-296-5P是一种影响发育,干细胞分化和癌症的信号通路的中央调节因子。我们假设MIR-296-5P可能通过调节其靶标素(涂鸦),最近涉及癌症干细胞性状和细胞运动性的极性蛋白质,可能是乳腺癌发作和进展。我们发现,与非肿瘤乳房实质相比,人乳腺癌组织中始终减少miR-296-5p水平,并且这种miRNA的低表达预测了经典临床病理参数的较短的无病生存率。此外,减少的miR-296-5p水平与整个系列中癌症的早期蔓延和子集中的远处转移显着相关。与其调节剂相比,与正常的实质相比,斯宾斯在原发性乳腺癌或局部乳腺癌或远处转移性病变中过表达并计量。值得注意的是,患有乳腺癌患者的整体存活率,转移性扩散和器官覆身与患者的整体存活,转移扩散和器官覆身有关。最后,将前体miR-296-5p直接注射到乳腺癌异种移植模型的肿瘤中显着降低了肿瘤生长。我们的研究结果表明,MIR-296-5P / SPIB轴在乳腺发生中起作用,乳腺-296-5P的治疗方法涌动乳腺癌肿瘤生长体内。 miR-296-5p的调节可以代表乳腺癌患者的新治疗选择。

著录项

  • 来源
    《Clinical Science》 |2014年第4期|共10页
  • 作者单位

    Department of Pathophysiology and Organ Transplantation University of Milan Milan Italy;

    Department of Pathophysiology and Organ Transplantation University of Milan Milan Italy;

    Department of Pathophysiology and Organ Transplantation University of Milan Milan Italy;

    Division of Medical Oncology San Paolo Hospital Milan Italy;

    Division of Medical Oncology San Paolo Hospital Milan Italy;

    Center for Preclinical Surgical Research University of Milan and Fondazione IRCCS Ca' Granda;

    Division of Medical Oncology San Paolo Hospital Milan Italy Department of Health Sciences;

    Division of Pathology Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Milan Milan;

    Department of Health Sciences University of Milan Milan Italy Division of Pathology San Paolo;

    Division of Pathology Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Milan Milan;

    Department of Pathophysiology and Organ Transplantation University of Milan Milan Italy;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 临床医学;
  • 关键词

    Breast carcinoma; MicroRNA; Neoplasm metastasis and recurrence; Prognosis; Scribble;

    机译:乳腺癌;microRNA;肿瘤转移和复发;预后;涂鸦;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号